Kymera Therapeutics' high P/S ratio could imply investors' b...
Kymera Therapeutics' high P/S ratio could imply investors' bullish stance outweighs analysts. However, without major growth improvement, the high P/S value may not sustain this positive sentiment, potentially making the stock overvalued.
Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) 35% Price Boost Is Out Of Tune With Revenues
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment